Page 4 - Dan Peer News Today

'It increases the sensitivity of cancer cells resistant to chemotherapy, while also reinvigorating immune cells.'

Tel Aviv University researchers develop nanoparticles able to utilize RNA to overcome resistance to both chemotherapy and immunotherapy in cancer treatments and open a new path to a personalized and precisely targeted battle against cancer

Ag-biotech company PlantArcBio and TAU to collaborate on the development of RNAi-based products and environmentally friendly solutions.

New Phase nanotech company aims to transform end-stage cancer from a likely death sentence to a chronic illness.

The ERC (European Research Council) grant, annually awarded by the European Union, is considered one of the most prestigious and important research grants in the world of science.

CRISPR-based cures will soon help combat all kinds of disease, from UTIs to leukemia. But terrifying implications of gene editing are abound as well

Tech investor, entrepreneur and Black Eyed Peas frontman will.i.am: "Silicon Valley wouldn't be Silicon Valley if it wasn't for the innovative minds, the spark that's happening here in Tel Aviv. IMPROVATE

/PRNewswire/ -- IMPROVATE, a platform for connecting change-makers and decision-makers, held its first annual International Innovation forum in Jerusalem on...

/PRNewswire/ -- IMPROVATE, a platform for connecting change-makers and decision-makers, held its first annual International Innovation forum in Jerusalem on...

Todos Medical starts trial of protease inhibitor to treat Covid-19 20 Apr 2021 (Last Updated April 20th, 2021 10:48) Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients. Share Article Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollo...